Analysis of proliferation markers and p53 expression in gliomas of astrocytic origin: Relationships and prognostic value

Journal of Neurosurgery

Volumn 86, Issue 1, 1997, Pages 121-130

  Cunningham, Julie M ^a   Kimmel, David W ^a   Scheithauer, Bernd W ^a   O'Fallon, Judith R ^a   Novotny, Paul J ^a   Jenkins, Robert B ^a  

^a MAYO CLINIC   (United States)

Author keywords

glioma; MIB 1; p53; proliferating cell nuclear antigen

Indexed keywords

BIOLOGICAL MARKER; PROTEIN P53;

ARTICLE; ASTROCYTOMA; CANCER GRADING; CELL CYCLE S PHASE; CHROMOSOME 17P; DIAGNOSTIC VALUE; FLOW CYTOMETRY; HUMAN; HUMAN TISSUE; MEDICAL DECISION MAKING; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; REPRODUCIBILITY; SURVIVAL TIME;

EID: 0031033359     PISSN: 00223085     EISSN: None     Source Type: Journal    
DOI: 10.3171/jns.1997.86.1.0121     Document Type: Article

References (72)

1. Alderson LM, Castleberg RL, Harsh GR IV, et al: Human gliomas with wild-type p53 express bcl-2. Cancer Res 55: 999-1001, 1995
2. Allegranza A, Girlando S, Arrigoni GL, et al: Proliferating cell nuclear antigen expression in central nervous system neoplasms. Virchows Arch A Pathol Anat Histopathol 419: 417-423, 1991
3. Ang LC, Plewes M, Tan L, et al: Proliferating cell nuclear antigen expression in the survival of astrocytoma patients. Can J Neurol Sci 21:306-310, 1994
4. Barbareschi M, Iuzzolino P, Pennella A, et al: p53 protein expression in central nervous system neoplasms. J Clin Pathol 45:583-586, 1992
5. Burger PC: Malignant astrocytic neoplasms: classification, pathologic anatomy, and response to treatment. Semin Oncol 13:16-26, 1986
6. Burger PC, Green SB: Patient age, histological features, and length of survival in patients with glioblastoma multiforme. Cancer 59:1617-1625, 1987
7. Burger PC, Vogel FS, Greed SB, et al: Glioblastoma multiforme and anaplastic astrocytoma: pathologic criteria and prognostic implications. Cancer 56:1106-1112, 1985
8. Chozick BS, Pezzullo JC, Epstein MH, et al: Prognostic implications of p53 overexpression in supratentorial astrocytic tumors. Neurosurgery 35:831-838, 1994
9. Chung R, Whaley J, Kley N, et al: TP53 gene mutations and 17p deletions in human astrocytomas. Genes Chromosom Cancer 3:323-331, 1991
10. Coltrera MD, Gown AM: PCNA/cyclin expression and BrdU uptake define different subpopulations in different cell lines. J Histochem Cytochem 39:23-30, 1991
11. Coltrera MD, Skelly M, Gown AM: Anti-PCNA antibody PC10 yields unreliable proliferation indexes in routinely processed, deparaffinized, formalin-fixed tissue. Appl Immunohistochem 1:193-200, 1993
12. Coons SW, Johnson PC, Pearl DK: Prognostic significance of flow cytometry deoxyribonucleic acid analysis of human astrocytomas. Neurosurgery 35:119-126, 1994
13. Coons SW, Johnson PC, Pearl DK, et al: Improving interobserver correlation in the classification and grading of astrocytomas. J Neuropathol Exp Neurol 52:288, 1993 (Abstract)
14. Cox DR: Regression models and life tables. J R Stat Soc B 34:187-220, 1972
15. Daumas-Duport C, Scheithauer BW, Kelly PJ: A histologic and cytologic method for the spatial definition of gliomas. Mayo Clin Proc 62:435-449, 1987
16. Daumas-Duport C, Scheithauer BW, O'Fallon J, et al: Grading of astrocytomas. A simple and reproducible method. Cancer 62:2152-2165, 1988
17. Dinapoli RP, Brown LD, Arusell RM, et al: Phase III comparative evaluation of PCNU and carmustine combined with radiation therapy for high grade glioma. J Clin Oncol 11: 1316-1321, 1993
18. El-Deiry WS, Tokino T, Velculescu VE, et al: WAF1, a potential mediator of p53 tumor suppression. Cell 75:817-825, 1993
19. Finlay CA: The mdm-2 oncogene can overcome wild-type p53 suppression of transformed cell growth. Mol Cell Biol 13:301-306, 1993
20. Finlay CA, Hinds PW, Tan TH, et al: Activating mutations for transformation by p53 produce a gene product that forms an hsc70-p53 complex with an altered half-life. Mol Cell Biol 8: 531-539, 1988
21. Ganju V, Jenkins RB, O'Fallon JR, et al: Prognostic factors in gliomas. A multivariate analysis of clinical, pathologic, flow cytometric, cytogenetic, and molecular markers. Cancer 74: 920-927, 1994
22. Haapasalo HK, Sallinen PK, Helén PT, et al: Comparison of three quantitation methods for PCNA immunostaining: applicability and relation to survival in 83 astrocytic neoplasms. J Pathol 171:207-214, 1993
23. Hall PA, Levison DA, Woods AL, et al: Proliferating cell nuclear antigen (PCNA) immunolocalization in paraffin sections: an index of cell proliferation with evidence of deregulated expression in some neoplasms. J Pathol 162:285-294, 1990
24. Harper JW, Adami GR, Wei N, et al: The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell 75:805-816, 1993
25. Hoshino T, Rodriguez LA, Cho KG, et al: Prognostic implications of the proliferative potential of low-grade astrocytomas. J Neurosurg 69:839-842, 1988
26. Iuzzolino P, Ghimenton C, Nicolato A, et al: p53 protein in low-grade astrocytomas: a study with long-term follow-up. Br J Cancer 69:586-591, 1994
27. Jain S, Filipe MI, Hall PA, et al: Prognostic value of proliferating cell nuclear antigen in gastric carcinoma. J Clin Pathol 44:655-659, 1991
28. Jaros E, Perry RH, Adam L, et al: Prognostic implications of p53 protein, epidermal growth factor receptor, and Ki-67 labelling in brain tumours. Br J Cancer 66:373-385, 1992
29. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
30. Karkavelas G, Mavropoulou S, Fountzilas G, et al: Correlation of proliferating cell nuclear antigen assessment, histologic parameters and age with survival in patients with glioblastoma multiforme. Anticancer Res 15:531-536, 1995
31. Kasten MB, Zhan Q, El-Deiry WS, et al: A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia telangiectasia. Cell 71:587-597, 1992
32. Cip1. Oncogene 11:1675-1683, 1995
33. Kepes JJ: Astrocytomas: old and newly recognized variants, their spectrum of morphology and antigen expression. Can J Neurol Surg 14:109-121, 1987
34. Key G, Becker MHG, Baron B, et al: New Ki-67-equivalent murine monoclonal antibodies (MIB 1-3) generated against bacterially expressed parts of the Ki-67 cDNA containing three 62 base pair repetitive elements encoding for the Ki-67 epitope. Lab Invest 68:629-636, 1993
35. Khoshyomn S, Maier H, Morimura T, et al: Immunostaining for proliferating cell nuclear antigen: its role in determination of proliferation in routinely processed human brain tumor specimens. Acta Neuropathol 86:582-589, 1993
36. Kordek R, Bratosiewicz J, Biernat W, et al: Expression of p53 protein, epidermal growth factor receptor (EGFR) and proliferating cell antigens in human gliomas. Folia Neuropathol 32:227-228, 1994
37. Korkolopoulou P, Christodoulou P, Lekka-Katsouli I, et al: Prognostic significance of proliferating cell nuclear antigen (PCNA) expression in gliomas. Histopathology 25:349-355, 1994
38. Krishna M, Smith TW, Recht LD: Expression of bcl-2 in reactive and neoplastic astrocytes: lack of correlation with presence or degree of malignancy. J Neurosurg 83:1017-1022, 1995
39. Kyritsis AP, Bondy ML, Hess KR, et al: Prognostic significance of p53 immunoreactivity in patients with glioma. Clin Cancer Res 1:1617-1622, 1995
40. LeBlanc M, Crowley J: Relative risk trees for censored survival data. Biometrics 48:411-425, 1992
41. Li Y, Jenkins CW, Nichols MA, et al: Cell cycle expression and p53 regulation of the cyclin-dependent kinase inhibitor p21. Oncogene 9:2261-2268, 1994
42. Lohr F, Wenz F, Haas S, et al: Comparison of proliferating cell nuclear antigen (PCNA) staining and BrdUrd-labelling index under different proliferative conditions in vitro by flow cytometry. Cell Prolif 28:93-104, 1995
43. Louis DN, Edgerton S, Thor AD, et al: Proliferating cell nuclear antigen and Ki-67 immunohistochemistry in brain tumors: a comparative study. Acta Neuropathol 81:675-679, 1991
44. Louis DN, von Deimling A, Chung RY, et al: Comparative study of p53 gene and protein alterations in human astrocytic tumors. J Neuropathol Exp Neurol 52:31-38, 1993
45. Mantel N: Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 50:163-170, 1966
46. McCormick D, Chong H, Hobbs C, et al: Detection of the Ki-67 antigen in fixed and wax-embedded sections with the monoclonal antibody MIB 1. Histopathology 22:355-360, 1993
47. Mercer WE, Shields MT, Lin D, et al: Growth suppression induced by wild-type p53 protein is accompanied by selective down-regulation of proliferating-cell nuclear antigen expression. Proc Natl Acad Sci USA 88:1958-1962, 1991
48. Michieli P, Chedid M, Lin D, et al: Induction of WAF1/CIP1 by a p53-independent pathway. Cancer Res 54:3391-3395, 1994
49. Morimura T, Kitz K, Stein H, et al: Determination of proliferative activities in human brain tumor specimens: a comparison of three methods. J Neurooncol 10:1-11, 1991
50. Newcomb EW, Madonia WJ, Pisharody S, et al: A correlative study of p53 protein alteration and p53 gene mutation in glioblastoma multiforme. Brain Pathol 3:229-235, 1993
51. Ng HK, Lo SY, Huang DP, et al: Paraffin section p53 protein immunohistochemistry in neuroectodermal tumors. Pathology 26:1-5, 1994
52. Nishizaki T, Orita T, Furutani Y, et al: Flow-cytometric DNA analysis and immunohistochemical measurement of Ki-67 and BUdR labeling indices in human brain tumors. J Neurosurg 70:379-384, 1989
53. Ohgaki H, Eibl RH, Schwab M, et al: Mutations of the p53 tumor suppressor gene in neoplasms of the human nervous system. Mol Carcinog 8:74-80, 1993
54. Onda K, Davis RL, Shibuya M, et al: Correlation between the bromodeoxyuridine labeling index and the MIB-1 and Ki-67 proliferating cell indices in cerebral gliomas. Cancer 74: 1921-1926, 1994
55. Rasheed BKA, McLendon RE, Herndon JE, et al: Alterations of the TP53 gene in human gliomas. Cancer Res 54:1324-1330, 1994
56. Revesv T, Alsanjari N, Darling JL, et al: Proliferating cell nuclear antigen (PCNA): expression in samples of human astrocytic gliomas. Neuropathol Appl Neurobiol 19:152-158, 1993
57. Ritter AM, Sawaya R, Hess KR, et al: Prognostic significance of bromodeoxyuridine labeling in primary and recurrent glioblastoma multiforme. Neurosurgery 35:192-198, 1994
58. Sabattini E, Gerdes J, Gherlinzoni F, et al: Comparison between the monoclonal antibodies Ki-67 and PC10 in 125 malignant lymphomas. J Pathol 169:397-403, 1993
59. Sallinen PK, Haapasalo HK, Visakorpi T, et al: Prognostication of astrocytoma patient survival by Ki-67 (MIB-1), PCNA, and S-phase fraction using archival paraffin-embedded samples. J Pathol 174:275-282, 1994
60. Sebo TJ, Roche PC, Witzig TE, et al: Proliferative activity in non-Hodgkin's lymphomas. A comparison of the bromode-oxyuridine labeling index with PCNA immunostaining and quantitative image analysis. Am J Clin Pathol 99:668-672, 1993
61. Shapiro WR: Treatment of neuroectodermal brain tumors. Ann Neurol 12:231-237, 1983
62. Shih YH, Kadota Y, Sato K, et al: Immunohistochemical expression of proliferating cell nuclear antigen (PCNA) in intracranial glioma and meningioma. Chung Hua I Hsueh Tsa Chih 53:193-197, 1994
63. Soini Y, Niemelä A, Kamel D, et al: p53 immunohistochemical positivity as a prognostic marker in intracranial tumours. APMIS 102:786-792, 1993
64. Theunissen PHMH, Blaauw G: Proliferating cell nuclear antigen immunostaining and survival in cerebral astrocytoma. Histopathology 23:75-79, 1993
65. Vojtěšek B, Bártek J, Midgley CA, et al: An immunochemical analysis of the human nuclear phosphoprotein p53. New monoclonal antibodies and epitope mapping using recombinant p53. J Immunol Methods 151:237-244, 1992
66. von Diemling A, Eibl RH, Ohgaki H, et al: p53 mutations are associated with 17p allelic loss in grade II and grade III astrocytoma. Cancer Res 52:2987-2990, 1992
67. Waga S, Hannon GJ, Beach D, et al: The p21 inhibitor of cyclin-dependent kinases controls DNA replication by interaction with PCNA. Nature 369:574-578, 1994
68. Wolf HK, Dittrich KL: Detection of proliferating cell nuclear antigen in diagnostic histopathology. J Histochem Cytochem 40:1269-1273, 1992
69. Xiong Y, Hannon GJ, Zhang H, et al: p21 is a universal inhibitor of cyclin kinases. Nature 366:701-704, 1993
70. Yu CCW, Filipe MI: Update on proliferation-associated antibodies applicable to formalin-fixed paraffin-embedded tissue and their clinical applications. Histochem J 25:843-853, 1993
71. Zaprianov Z, Christov K: Histological grading, DNA content, cell proliferation and survival of patients with astroglial tumors. Cytometry 9:380-386, 1988
72. Zuber P, Hamou MF, de Tribolet N: Identification of proliferating cells in human gliomas using the monoclonal antibody Ki-67. Neurosurgery 22:364-368, 1988